We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+20.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$41.5M
Cap. Flow
+$31.8M
Cap. Flow %
14.78%
Top 10 Hldgs %
55.52%
Holding
68
New
22
Increased
11
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$11.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.2M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$8.59M
4
GSK icon
GSK
GSK
+$8.44M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$6.04M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$14.1M
2
EHTH icon
eHealth
EHTH
+$4.18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$4.01M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$2.62M
5
PBYI icon
Puma Biotechnology
PBYI
+$2.38M

Sector Composition

Rank Sector Weight
1 Healthcare 75.31%
2 Real Estate 9.99%
3 Miscellaneous 7.87%
4 Industrials 6.33%
5 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QCP
1
DELISTED
Quality Care Properties, Inc.
QCP
$20M 9.3%
1,030,661
+782,015
+315% +$11.7M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$15.8M 7.33%
60,000
-30,000
-33% -$8.19M
RCM
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$13.6M 6.33%
1,909,887
+268,009
+16% +$1.51M
RDUS
4
DELISTED
Radius Health, Inc.
RDUS
$12M 5.57%
333,738
+139,237
+72% +$5.03M
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
$11.4M 5.31%
210,778
-30,702
-13% -$1.72M
ABLX
6
DELISTED
Ablynx NV
ABLX
$9.92M 4.61%
181,891
+81,012
+80% +$4.01M
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
$9.66M 4.49%
78,201
+50,831
+186% +$6.04M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$31.7B
$9.4M 4.36%
+78,893
New +$10.2M
GSK icon
9
GSK
GSK
$102B
$8.95M 4.16%
+181,267
New +$8.44M
ARNA
10
DELISTED
Arena Pharmaceuticals Inc
ARNA
$8.72M 4.05%
+220,788
New +$8.59M
ENSG icon
11
The Ensign Group
ENSG
$10.1B
$8.59M 3.99%
348,384
-6,254
-2% -$149K
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$8.19M 3.8%
204,546
-13,832
-6% -$549K
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$137B
$7.31M 3.39%
44,822
-13,300
-23% -$2.17M
ARRY
14
DELISTED
Array Biopharma Inc
ARRY
$5.84M 2.71%
357,727
-880,076
-71% -$14.1M
SNY icon
15
Sanofi
SNY
$107B
$5.53M 2.57%
137,972
-50,000
-27% -$2.08M
NVRO
16
DELISTED
NEVRO CORP.
NVRO
$5.27M 2.45%
60,850
-4,000
-6% -$323K
TLGT
17
DELISTED
Teligent, Inc
TLGT
$5.21M 2.42%
155,038
-11,051
-7% -$352K
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$3.87M 1.8%
+24,000
New +$4.07M
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$12.5B
$3.73M 1.73%
46,000
+300
+0.7% +$25.7K
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$2.94M 1.37%
51,523
-34,217
-40% -$2.2M
ARGX icon
21
argenx
ARGX
$64B
$2.88M 1.34%
35,784
+8,124
+29% +$614K
ABT icon
22
Abbott
ABT
$195B
$2.87M 1.33%
+47,900
New +$2.89M
TGTX icon
23
TG Therapeutics
TGTX
$8.26B
$2.13M 0.99%
+150,000
New +$1.92M
ABMD
24
DELISTED
Abiomed Inc
ABMD
$2.06M 0.96%
7,094
-1,500
-17% -$380K
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.05M 0.95%
42,000
-8,000
-16% -$416K
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Eversept Partners held 68 positions worth $215M, up 24% from $174M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $31.8M of net new capital in Q1 2018, opening 22 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 75% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $14.1M trimmed.

  • Eversept Partners's largest Q1 2018 buy was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.
  • Eversept Partners added most to Quality Care Properties, Inc. in Q1 2018, an estimated $11.7M increase.
  • Eversept Partners's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $14.1M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q1 2018, selling an estimated $4.01M.
  • Eversept Partners's ten largest holdings make up 56% of its $215M portfolio in Q1 2018.
  • Eversept Partners opened 22 new positions and closed 11 in Q1 2018.
  • Eversept Partners's portfolio value rose 24% quarter-over-quarter to $215M.

Based on Eversept Partners's 13F filing for Q1 2018, filed 14 May 2018.